Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy

Md Selim Ahmed, Se Eun Byeon, Yideul Jeong, Mohammad Alam Miah, Md Salahuddin, Yoon Lee, Sung Soo Park, Yong Soo Bae

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Dab2 is an adapter protein involved in receptor-mediated signaling, endocytosis, cell adhesion, hematopoietic cell differentiation, and angiogenesis. It plays a pivotal role in controlling cellular homeostasis. In the immune system, the Dab2 is a Foxp3 target gene and is required for regulatory T (Treg) cell function. Dab2 expression and its biological function in dendritic cells (DCs) have not been described. In this study, we found that Dab2 was significantly induced during the development of mouse bone marrow (BM)-derived DCs (BMDCs) and human monocyte-derived DCs (MoDCs). Even in a steady state, Dab2 was expressed in mouse splenic DCs (spDCs). STAT5 activation, Foxp3 expression, and hnRNPE1 activation mediated by PI3K/Akt signaling were required for Dab2 expression during GM-CSF-derived BMDC development regardless of TGF-β signaling. Dab2-silencing was accompanied by enhanced IL-12 and IL-6 expression, and an improved capacity of DC for antigen uptake, migration and T cell stimulation, which generated strong CTL in vaccinated mice. Vaccination with Dab2-silenced DCs inhibited tumor growth more effectively than did vaccination with wild type DCs. Dab2-overexpression abrogated the efficacy of the DC vaccine in DC-based tumor immunotherapy. These data strongly suggest that Dab2 might be an intrinsic negative regulator of the immunogenicity of DCs, thus might be an attractive molecular target to improve DC vaccine efficacy.

Original languageEnglish
Number of pages1
JournalOncoImmunology
Volume4
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Immunotherapy
Dendritic Cells
Regulatory T-Lymphocytes
Vaccination
Vaccines
Interleukin-12
Granulocyte-Macrophage Colony-Stimulating Factor
Endocytosis
Phosphatidylinositol 3-Kinases
Cell Adhesion
Monocytes
Cell Differentiation
Immune System
Interleukin-6
Neoplasms
Homeostasis
Bone Marrow
T-Lymphocytes
Antigens
Growth

Keywords

  • Dab2
  • dendritic cells
  • immunogenicity
  • molecular target

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy. / Ahmed, Md Selim; Byeon, Se Eun; Jeong, Yideul; Miah, Mohammad Alam; Salahuddin, Md; Lee, Yoon; Park, Sung Soo; Bae, Yong Soo.

In: OncoImmunology, Vol. 4, No. 1, 01.01.2015.

Research output: Contribution to journalArticle

Ahmed, Md Selim ; Byeon, Se Eun ; Jeong, Yideul ; Miah, Mohammad Alam ; Salahuddin, Md ; Lee, Yoon ; Park, Sung Soo ; Bae, Yong Soo. / Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy. In: OncoImmunology. 2015 ; Vol. 4, No. 1.
@article{377f243576a24332a2d76b9eb4577cf0,
title = "Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy",
abstract = "Dab2 is an adapter protein involved in receptor-mediated signaling, endocytosis, cell adhesion, hematopoietic cell differentiation, and angiogenesis. It plays a pivotal role in controlling cellular homeostasis. In the immune system, the Dab2 is a Foxp3 target gene and is required for regulatory T (Treg) cell function. Dab2 expression and its biological function in dendritic cells (DCs) have not been described. In this study, we found that Dab2 was significantly induced during the development of mouse bone marrow (BM)-derived DCs (BMDCs) and human monocyte-derived DCs (MoDCs). Even in a steady state, Dab2 was expressed in mouse splenic DCs (spDCs). STAT5 activation, Foxp3 expression, and hnRNPE1 activation mediated by PI3K/Akt signaling were required for Dab2 expression during GM-CSF-derived BMDC development regardless of TGF-β signaling. Dab2-silencing was accompanied by enhanced IL-12 and IL-6 expression, and an improved capacity of DC for antigen uptake, migration and T cell stimulation, which generated strong CTL in vaccinated mice. Vaccination with Dab2-silenced DCs inhibited tumor growth more effectively than did vaccination with wild type DCs. Dab2-overexpression abrogated the efficacy of the DC vaccine in DC-based tumor immunotherapy. These data strongly suggest that Dab2 might be an intrinsic negative regulator of the immunogenicity of DCs, thus might be an attractive molecular target to improve DC vaccine efficacy.",
keywords = "Dab2, dendritic cells, immunogenicity, molecular target",
author = "Ahmed, {Md Selim} and Byeon, {Se Eun} and Yideul Jeong and Miah, {Mohammad Alam} and Md Salahuddin and Yoon Lee and Park, {Sung Soo} and Bae, {Yong Soo}",
year = "2015",
month = "1",
day = "1",
doi = "10.4161/2162402X.2014.984550",
language = "English",
volume = "4",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy

AU - Ahmed, Md Selim

AU - Byeon, Se Eun

AU - Jeong, Yideul

AU - Miah, Mohammad Alam

AU - Salahuddin, Md

AU - Lee, Yoon

AU - Park, Sung Soo

AU - Bae, Yong Soo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Dab2 is an adapter protein involved in receptor-mediated signaling, endocytosis, cell adhesion, hematopoietic cell differentiation, and angiogenesis. It plays a pivotal role in controlling cellular homeostasis. In the immune system, the Dab2 is a Foxp3 target gene and is required for regulatory T (Treg) cell function. Dab2 expression and its biological function in dendritic cells (DCs) have not been described. In this study, we found that Dab2 was significantly induced during the development of mouse bone marrow (BM)-derived DCs (BMDCs) and human monocyte-derived DCs (MoDCs). Even in a steady state, Dab2 was expressed in mouse splenic DCs (spDCs). STAT5 activation, Foxp3 expression, and hnRNPE1 activation mediated by PI3K/Akt signaling were required for Dab2 expression during GM-CSF-derived BMDC development regardless of TGF-β signaling. Dab2-silencing was accompanied by enhanced IL-12 and IL-6 expression, and an improved capacity of DC for antigen uptake, migration and T cell stimulation, which generated strong CTL in vaccinated mice. Vaccination with Dab2-silenced DCs inhibited tumor growth more effectively than did vaccination with wild type DCs. Dab2-overexpression abrogated the efficacy of the DC vaccine in DC-based tumor immunotherapy. These data strongly suggest that Dab2 might be an intrinsic negative regulator of the immunogenicity of DCs, thus might be an attractive molecular target to improve DC vaccine efficacy.

AB - Dab2 is an adapter protein involved in receptor-mediated signaling, endocytosis, cell adhesion, hematopoietic cell differentiation, and angiogenesis. It plays a pivotal role in controlling cellular homeostasis. In the immune system, the Dab2 is a Foxp3 target gene and is required for regulatory T (Treg) cell function. Dab2 expression and its biological function in dendritic cells (DCs) have not been described. In this study, we found that Dab2 was significantly induced during the development of mouse bone marrow (BM)-derived DCs (BMDCs) and human monocyte-derived DCs (MoDCs). Even in a steady state, Dab2 was expressed in mouse splenic DCs (spDCs). STAT5 activation, Foxp3 expression, and hnRNPE1 activation mediated by PI3K/Akt signaling were required for Dab2 expression during GM-CSF-derived BMDC development regardless of TGF-β signaling. Dab2-silencing was accompanied by enhanced IL-12 and IL-6 expression, and an improved capacity of DC for antigen uptake, migration and T cell stimulation, which generated strong CTL in vaccinated mice. Vaccination with Dab2-silenced DCs inhibited tumor growth more effectively than did vaccination with wild type DCs. Dab2-overexpression abrogated the efficacy of the DC vaccine in DC-based tumor immunotherapy. These data strongly suggest that Dab2 might be an intrinsic negative regulator of the immunogenicity of DCs, thus might be an attractive molecular target to improve DC vaccine efficacy.

KW - Dab2

KW - dendritic cells

KW - immunogenicity

KW - molecular target

UR - http://www.scopus.com/inward/record.url?scp=84938718469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938718469&partnerID=8YFLogxK

U2 - 10.4161/2162402X.2014.984550

DO - 10.4161/2162402X.2014.984550

M3 - Article

AN - SCOPUS:84938718469

VL - 4

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 1

ER -